Trevi Therapeutics, Inc. Common Stock
TRVI
TRVI: Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
moreShow TRVI Financials
Recent trades of TRVI by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by TRVI's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Treatment of chronic cough, breathlessness and dyspnea May. 30, 2023
-
Patent Title: Methods for treating pruritus Mar. 26, 2019
-
Patent Title: Compounds for treating pruritic conditions Apr. 18, 2017
-
Patent Title: Methods for treating pruritus Mar. 24, 2015
-
Patent Title: Methods for treating pruritis Jan. 27, 2015
-
Patent Title: Methods for treatment of pruritis Jan. 28, 2014
Federal grants, loans, and purchases
Followers on TRVI's company Twitter account
Number of mentions of TRVI in WallStreetBets Daily Discussion
Recent insights relating to TRVI
Recent picks made for TRVI stock on CNBC
ETFs with the largest estimated holdings in TRVI
Flights by private jets registered to TRVI